Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis

Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis

Abstract Background and Aim Molecular‐targeted agents such as lenvatinib and sorafenib have been approved to treat hepatocellular carcinoma (HCC). However, the choice between these two agents in the primary treatment for advanced HCC is still under debate with conflicting results. We sought to evalu...

Full description

Bibliographic Details
Main Authors: Vikash Jaiswal, Maha Hameed, Sidra Naz, Poulami Roy, Novonil Deb, Janta Ukrani, Gautham Varun Krishna Mohan, Amira M Taha, Helen Huang, Vikash Kumar, Bhavyakumar Vachhani, Abdelrahman M Attia, Supti D Nath, Mostafa A Solimn, Dattatreya Mukherjee
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:JGH Open
Subjects:
hepatocellular carcinoma
lenvatinib
mortality
sorafenib
Online Access:https://doi.org/10.1002/jgh3.12999

Internet

https://doi.org/10.1002/jgh3.12999

Similar Items